SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

ABO-801

ABEO·Abeona Therapeutics Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2 completed / Phase 3-ready
Time to market
ABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.
Why 4/10
ABO-801 was just acquired on November 9, 2026 and is Phase 3-ready, but no Phase 3 trial start date or PDUFA has been announced. The next drug-specific catalyst (Phase 3 initiation or data readout) is likely more than 12 months away. The stock's primary value driver remains the approved, commercial-stage gene therapy ZEVASKYN. ABO-801 is a pipeline expansion asset with no near-term binary catalyst, capping the impact score at 4.
Actionable Insight NEUTRAL

Watch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.

Price Chart

Loading chart...

Executive Summary

ABO-801 (formerly APT-1011) is a Phase 3-ready, once-daily oral therapy for eosinophilic esophagitis (EoE) that Abeona Therapeutics acquired from Ellodi Pharmaceuticals on November 9, 2026 for $20M in stock plus up to $60M in milestones and royalties. The deal was announced concurrently with a $30M PIPE financing at $3.75/share and Q3 2026 earnings showing ZEVASKYN revenue of $13.5M (up 18% QoQ). ABO-801 has FDA Orphan Drug and Fast Track designations and demonstrated positive Phase 2 data (FLUTE-2 trial) showing higher rates of complete symptomatic response at 12 weeks versus placebo. The stock traded down ~16% in pre-market on the dilutive financing and activist investor pressure. ABO-801 diversifies Abeona beyond its approved gene therapy ZEVASKYN but has no near-term binary catalyst, as a Phase 3 trial has not yet been initiated.

How It Works

ABO-801 is a once-daily, oral therapy for eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. It is designed to be swallowed as a liquid, allowing it to coat the esophagus directly and reduce the allergic-type inflammation that causes difficulty swallowing and other symptoms. The drug has completed Phase 2 testing and is ready for Phase 3 trials.

Trial Status

ABO-801 (as APT-1011) completed the Phase 2 FLUTE-2 trial, which showed a higher rate of complete symptomatic response at 12 weeks compared to placebo, with improvements maintained up to 38 weeks. The drug has not yet initiated a Phase 3 trial under Abeona's sponsorship.

The Two-Sided Case

▲ Bull Case6
Pipeline diversification: ABO-801 adds a Phase 3-ready, non-gene-therapy asset to Abeona's pipeline, reducing single-asset dependence on ZEVASKYN.
Favorable deal structure: Abeona acquired ABO-801 for $20M in stock with no upfront cash, plus up to $60M in milestones and tiered royalties, limiting downside if the drug fails.
FDA designations: ABO-801 has both FDA Orphan Drug and Fast Track designations for eosinophilic esophagitis, which can accelerate development and provide market exclusivity.
Positive Phase 2 data: The FLUTE-2 trial showed APT-1011 (now ABO-801) demonstrated a higher rate of complete symptomatic response at 12 weeks compared to placebo, with improvements maintained up to 38 weeks.
Strong analyst support: 12 of 13 analysts rate ABEO Buy/Strong Buy, with a mean price target of $18.88 (352% implied upside from the $4.17 close), though targets predate today's PIPE and acquisition news.
ZEVASKYN commercial momentum: Q3 2026 net ZEVASKYN revenue of $13.5M, up 18% sequentially, with 8 Qualified Treatment Centers activated.
▼ Bear Case5
Significant dilution: the $30M PIPE at $3.75/share and $20M stock consideration for the acquisition dilute existing holders by roughly 13-25%, and the stock was down ~16% in pre-market trading on the announcement day.
Activist pressure: James Russell disclosed a 6.1% stake on October 23, 2026 and is pushing for board and leadership changes, adding governance uncertainty.
Insider selling: Four senior executives (CEO, CFO, CLO, CCO) sold shares on September 29, 2026 at ~$5.16, and a director sold on September 1, 2026 at ~$5.86.
Phase 3 risk: ABO-801 is Phase 3-ready but has not yet started a pivotal trial; Phase 3 outcomes are inherently uncertain and the EoE competitive landscape includes tezepelumab (AstraZeneca) and ESO-101 (EsoCap).
Abeona remains unprofitable: Q3 2026 net loss of $4.8M, though narrower than expected, and the company is still burning cash despite ZEVASKYN commercial revenue.

Upcoming Catalysts

  • Initiation of Phase 3 trial for ABO-801 in eosinophilic esophagitis (date TBD)
  • Registration statement filing for PIPE shares (due within 15 days of November 9, 2026)
  • Activist investor James Russell potential proxy contest or board changes
  • ZEVASKYN quarterly revenue growth trajectory and Qualified Treatment Center expansion

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Abeona Therapeutics Inc. Press Release ABEO ·Originating report

Sources · 10

Hover a chip for the title
1 markets.businessinsider.com2 rttnews.com3 tmcnet.com4 streetinsider.com5 sec.gov6 sec.gov7 globenewswire.com8 globenewswire.com9 marketscreener.com10 prnewswire.com